Anthem Biosciences IPO subscribed over 3.48x on day 2

Anthem Biosciences IPO subscribed over 3.48x on its Second day of subscription, wherein QIB subscribed 0.62x, NII subscribed 10.26x, and RII subscribed 2.21x.

Anthem Biosciences IPO Subscription started on Monday, July 14, and will close on July 16, 2025, as scheduled. The price band is set at ₹540 to ₹570 per share with a face value of ₹2.

Anthem Biosciences IPO Subscription Status

Anthem Biosciences IPO subscribed over 3.48x on its Second day till 05.00 PM on 15th July.

Anthem Biosciences IPO subscription QIB investors portion is 0.62x times, while NII subscribers subscribed 10.42x times, and RII investors subscribed 2.21x times.
The company has received bids for 14,51,62,680 shares against 4,17,50,321 shares on offer on the Second day.
Anthem Biosciences IPO subscribed over 3.48x on day 2.
Anthem Biosciences IPO subscribed over 0.77x on day 1.

About Anthem Biosciences IPO

Anthem Biosciences Limited, founded in 2006, is one of the growing innovation-driven and technology-focused Contract Research, Development and Manufacturing Organizations (“CRDMO”) with end-to-end operations covering drug discovery, development, and manufacturing. Anthem Biosciences is one of the few companies in India with integrated capabilities in New Chemical Entities (NCE) and New Biological Entities (NBE) throughout drug discovery, development, and commercial manufacturing.

Anthem Biosciences is a one-stop service provider engaged in serving a wide range of customers, including emerging biotech companies and large pharmaceutical firms around the world. The company is involved in the manufacturing of specialized fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. The company has supplied to over 150 customers, from small biotech to large pharmaceutical companies, as of March 31, 2024. Currently, the company has a team of 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, and chemical engineers.

Anthem Biosciences IPO Company Financial Report

The company reported revenue of ₹1,930.29 crores in 2025 against ₹1,483.07 crores in 2024. The company reported a profit of ₹451.26 crores in 2025 against a profit of ₹367.31 crores in 2024.

Anthem Biosciences IPO GMP:

Anthem Biosciences IPO GMP was ₹117 as of Tuesday, July 15th, 2025. That indicates the IPO is trading at ₹687 with a ₹117 premium in the grey market against the issue price of ₹570.

Vijay Prajapati

An experienced stock market professional with expertise in IPO research, market insights, and equity strategies. With a strong background in research and capital markets, he delivers comprehensive coverage on upcoming IPOs, subscription patterns, grey market premium (GMP), and post-listing performance, along with detailed reviews, recommendations, and technical analysis.

Add IPOWatch to your Google News feed.

Disclaimer: This content is provided strictly for educational and informational purposes. The securities or investments mentioned are not to be considered as investment advice or recommendations. The Investors are advised to do their own research or connect with a financial advisor before making any investment decisions.